$6.53
0.000.00%
At close: -
$6.53
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Bioventus Analyst Ratings and Price Targets | NASDAQ:BVS | Benzinga
Bioventus Inc has a consensus price target of $11.25 based on the ratings of 7 analysts. The high is $17 issued by Craig-Hallum on September 27, 2024. The low is $2.5 issued by Goldman Sachs on November 30, 2022. The 3 most-recent analyst ratings were released by Canaccord Genuity, JP Morgan, and Canaccord Genuity on March 17, 2025, December 17, 2024, and November 6, 2024, respectively. With an average price target of $14.33 between Canaccord Genuity, JP Morgan, and Canaccord Genuity, there's an implied 119.50% upside for Bioventus Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
JP Morgan
Canaccord Genuity
Craig-Hallum
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Bioventus
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/17/2025 | Buy Now | 129.71% | Canaccord Genuity | Caitlin Cronin38% | $15 → $15 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 99.08% | JP Morgan | Robbie Marcus67% | $12 → $13 | Upgrade | Underweight → Neutral | Get Alert |
| 11/06/2024 | Buy Now | 129.71% | Canaccord Genuity | William Plovanic59% | $12 → $15 | Maintains | Buy | Get Alert |
| 09/27/2024 | Buy Now | 160.34% | Craig-Hallum | Alexander Nowak53% | $12 → $17 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 83.77% | Canaccord Genuity | William Plovanic59% | $8 → $12 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | 83.77% | Craig-Hallum | Alexander Nowak53% | $9 → $12 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 22.51% | Canaccord Genuity | William Plovanic59% | $7 → $8 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 37.83% | Craig-Hallum | Alexander Nowak53% | $6 → $9 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | 7.2% | Canaccord Genuity | William Plovanic59% | $3.66 → $7 | Upgrade | Hold → Buy | Get Alert |
| 04/03/2023 | Buy Now | -23.43% | Craig-Hallum | Alexander Nowak53% | $10 → $5 | Maintains | Hold | Get Alert |
| 11/30/2022 | Buy Now | -61.72% | Goldman Sachs | Amit Hazan56% | $13 → $2.5 | Maintains | Neutral | Get Alert |
| 11/22/2022 | Buy Now | — | Craig-Hallum | Alexander Nowak53% | — | Downgrade | Buy → Hold | Get Alert |
| 11/10/2022 | Buy Now | -23.43% | Morgan Stanley | Drew Ranieri47% | $11 → $5 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | — | Canaccord Genuity | Kyle Rose68% | — | Downgrade | Buy → Hold | Get Alert |
| 11/09/2022 | Buy Now | — | JP Morgan | Robbie Marcus67% | — | Downgrade | Overweight → Underweight | Get Alert |
| 10/11/2022 | Buy Now | 68.45% | Morgan Stanley | Drew Ranieri47% | $12 → $11 | Maintains | Overweight | Get Alert |
| 09/07/2022 | Buy Now | 99.08% | Goldman Sachs | Amit Hazan56% | $15 → $13 | Maintains | Neutral | Get Alert |
| 08/12/2022 | Buy Now | 83.77% | Morgan Stanley | Drew Ranieri47% | $11 → $12 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Bioventus (BVS) stock?
The latest price target for Bioventus (NASDAQ:BVS) was reported by Canaccord Genuity on March 17, 2025. The analyst firm set a price target for $15.00 expecting BVS to rise to within 12 months (a possible 129.71% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bioventus (BVS)?
The latest analyst rating for Bioventus (NASDAQ:BVS) was provided by Canaccord Genuity, and Bioventus maintained their buy rating.
When was the last upgrade for Bioventus (BVS)?
The last upgrade for Bioventus Inc happened on December 17, 2024 when JP Morgan raised their price target to $13. JP Morgan previously had an underweight for Bioventus Inc.
When was the last downgrade for Bioventus (BVS)?
The last downgrade for Bioventus Inc happened on November 22, 2022 when Craig-Hallum changed their price target from N/A to N/A for Bioventus Inc.
When is the next analyst rating going to be posted or updated for Bioventus (BVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.
Is the Analyst Rating Bioventus (BVS) correct?
While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $15.00 to $15.00. The current price Bioventus (BVS) is trading at is $6.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
